Quest Diagnostics Inc. vs. GRAIL, Inc. Common Stock
Quest Diagnostics Inc. (DGX) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| DGX | GRAL | |
|---|---|---|
| Market Cap | $26.08 billion | $5.92 billion |
| Revenue (TTM) | $11.56 billion | $165.26 million |
| Net Income (TTM) | $1.11 billion | $-391,587,000 |
DGX leads on 3 of 3 size & scale factors.
Valuation
| DGX | GRAL | |
|---|---|---|
| P/E Ratio | 25.23 | — |
| Price / Book | 3.34 | 2.33 |
| Price / Sales | 2.26 | 35.85 |
DGX and GRAL split the valuation factors evenly.
Profitability
| DGX | GRAL | |
|---|---|---|
| Net Margin | 9.63% | -236.95% |
| Return on Equity | 14.23% | -15.40% |
DGX leads on 2 of 2 profitability factors.
Dividend
| DGX | GRAL | |
|---|---|---|
| Dividend Yield | 1.45% | — |
| Payout Ratio | 36.52 | — |
DGX and GRAL split the dividend factors evenly.
Risk & Sentiment
| DGX | GRAL | |
|---|---|---|
| Short Interest | 4.76% | 5.12% |
DGX leads on 1 of 1 risk & sentiment factors.
Dig deeper: DGX overview, DGX financials, GRAL overview, GRAL financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.